Stevanato Group (NYSE:STVN – Get Free Report) and Siga Technologies (NASDAQ:SIGA – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.
Institutional & Insider Ownership
55.4% of Siga Technologies shares are held by institutional investors. 2.0% of Siga Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Analyst Ratings
This is a summary of current ratings and price targets for Stevanato Group and Siga Technologies, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Stevanato Group | 0 | 2 | 3 | 1 | 2.83 |
Siga Technologies | 0 | 0 | 0 | 0 | 0.00 |
Profitability
Net Margins | Return on Equity | Return on Assets | |
Stevanato Group | 11.73% | 10.34% | 6.21% |
Siga Technologies | 45.73% | 40.52% | 35.62% |
Risk and Volatility
Stevanato Group has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Comparatively, Siga Technologies has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500.
Valuation and Earnings
This table compares Stevanato Group and Siga Technologies”s revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Stevanato Group | $1.19 billion | 5.73 | $127.45 million | €0.54 | 41.89 |
Siga Technologies | $138.72 million | 4.45 | $59.21 million | $1.13 | 7.64 |
Stevanato Group has higher revenue and earnings than Siga Technologies. Siga Technologies is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.
About Stevanato Group
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
About Siga Technologies
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.
Receive News & Ratings for Stevanato Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stevanato Group and related companies with MarketBeat.com's FREE daily email newsletter.